Sense Neuro Diagnostics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Series BB
- (In Progress)
- Latest Deal Amount
-
$9M
- Investors
-
21
Sense Neuro Diagnostics General Information
Description
Developer of AI and machine learning-enabled non-invasive neurodiagnostic medical devices designed to rapidly detect intracranial bleeding and other acute neurological conditions at the point of care. The company offers proprietary RF-based sensing hardware integrated with advanced machine learning algorithms, enabling ambulances, emergency departments, intensive care units, and military medical units to conduct real-time brain assessment without reliance on imaging or specialised infrastructure for faster triage and clinical decision-making.
Contact Information
Website
www.senseneuro.comCorporate Office
- 6037 Schumacher Park Drive
- West Chester, OH 45069
- United States
Corporate Office
- 6037 Schumacher Park Drive
- West Chester, OH 45069
- United States
Sense Neuro Diagnostics Timeline
Sense Neuro Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 19. Later Stage VC (Series BB) | 19-Jan-2026 | $9M | In Progress | Generating Revenue | ||
| 18. Later Stage VC | 03-Oct-2025 | Completed | Generating Revenue | |||
| 17. Later Stage VC (Series B) | 28-Nov-2023 | Completed | Generating Revenue | |||
| 16. Accelerator/Incubator | 01-Dec-2022 | Completed | Generating Revenue | |||
| 15. Grant | 27-Oct-2022 | Completed | Generating Revenue | |||
| 14. Accelerator/Incubator | 28-Mar-2022 | Completed | Generating Revenue | |||
| 13. Grant | 02-Aug-2021 | Completed | Clinical Trials - General | |||
| 12. Later Stage VC | 01-Apr-2021 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series B2) | 01-Sep-2020 | $1.43M | $7.56M | Completed | Clinical Trials - General | |
| 10. Grant | 15-Sep-2019 | $350K | $6.13M | Completed | Clinical Trials - General |
Sense Neuro Diagnostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B5 | ||||||||
| Series B4 | ||||||||
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A3 | ||||||||
| Series A2 | 210,357 | $0.000010 | 8% | $1.32 | $1.32 | 1x | $1.32 | 3.49% |
| Series A1 | 123,705 | $0.000010 | 8% | $1.27 | $1.27 | 1x | $1.27 | 2.05% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Sense Neuro Diagnostics Comparisons
Industry
Financing
Details
Sense Neuro Diagnostics Competitors (3)
One of Sense Neuro Diagnostics’s 3 competitors is InfraScan, a Venture Capital-Backed company based in Radnor, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InfraScan | Venture Capital-Backed | Radnor, PA | ||||
| EMvision Medical Devices | Corporation | Sydney, Australia | ||||
| BrainScope | Venture Capital-Backed | Rockville, MD |
Sense Neuro Diagnostics Patents
Sense Neuro Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11413215-B2 | Methods for evaluating effectiveness of resuscitation efforts during a cardiac crisis | Active | 23-Oct-2017 | ||
| US-20190117500-A1 | Methods for evaluating effectiveness of resuscitation efforts during a cardiac crisis | Active | 23-Oct-2017 | ||
| WO-2019083958-A1 | Methods for evaluating effectiveness of resuscitation efforts during a cardiac crisis | Inactive | 23-Oct-2017 | A61B5/0265 |
Sense Neuro Diagnostics Signals
Sense Neuro Diagnostics Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alloy Growth Lab | Accelerator/Incubator | Minority | ||
| Bearcat Ventures | Venture Capital | Minority | ||
| QCA First Funds | Venture Capital | Minority | ||
| UC Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Sense Neuro Diagnostics FAQs
-
When was Sense Neuro Diagnostics founded?
Sense Neuro Diagnostics was founded in 2013.
-
Where is Sense Neuro Diagnostics headquartered?
Sense Neuro Diagnostics is headquartered in West Chester, OH.
-
What is the size of Sense Neuro Diagnostics?
Sense Neuro Diagnostics has 11 total employees.
-
What industry is Sense Neuro Diagnostics in?
Sense Neuro Diagnostics’s primary industry is Other Devices and Supplies.
-
Is Sense Neuro Diagnostics a private or public company?
Sense Neuro Diagnostics is a Private company.
-
What is the current valuation of Sense Neuro Diagnostics?
The current valuation of Sense Neuro Diagnostics is .
-
What is Sense Neuro Diagnostics’s current revenue?
The current revenue for Sense Neuro Diagnostics is .
-
How much funding has Sense Neuro Diagnostics raised over time?
Sense Neuro Diagnostics has raised $32M.
-
Who are Sense Neuro Diagnostics’s investors?
Alloy Growth Lab, Bearcat Ventures, QCA First Funds, UC Ventures, and are 5 of 21 investors who have invested in Sense Neuro Diagnostics.
-
Who are Sense Neuro Diagnostics’s competitors?
InfraScan, EMvision Medical Devices, and BrainScope are competitors of Sense Neuro Diagnostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process